Wirkstoffe & Arzneimittelsicherheit

Wechselwirkungen · Truqap

TRUQAP 160 mg film-coated tablets TRUQAP 200 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 10

HOS-150749 · Präparat HOS-100380

Strong CYP3A4 inhibitors Co-administration of TRUQAP with strong CYP3A4 inhibitors increases capivasertib concentration, which may increase the risk of TRUQAP toxicity. Co-administration with strong CYP3A4 inhibitors should be avoided (e.g. boceprevir, ceritinib, clarithromycin, cobicistat, conivaptan, ensitrelvir, idelalisib, indinavir, itraconazole, josamycin, ketoconazole, lonafarnib, mibefradil, mifepristone, nefazodone, nelfinavir, posaconazole, ribociclib, ritonavir, saquinavir, telaprevir, telithromycin, troleandomycin, tucatinib, voriconazole, grapefruit or grapefruit juice). If co-administration cannot be avoided, TRUQAP dose should be reduced (see section 4.2). Co-administration of multiple 200 mg doses of the strong CYP3A4 inhibitor itraconazole increased capivasertib total exposure (AUCinf) and the peak concentration (Cmax) by 95% and 70%, respectively, relative to capivasertib given alone.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): indinavir (HOS-084518) ceritinib (HOS-086215) josamycin (HOS-113844) nefazodone (HOS-084519) ensitrelvir (HOS-150750) nelfinavir (HOS-084520) lonafarnib (HOS-150752) ketoconazole (HOS-084513) cobicistat (HOS-088111) conivaptan (HOS-128737) mibefradil (HOS-125440) grapefruit juice (HOS-088787) voriconazole (HOS-084524) telaprevir (HOS-090618) telithromycin (HOS-084523) itraconazole (HOS-084516) saquinavir (HOS-084522) boceprevir (HOS-090617) clarithromycin (HOS-084517) ribociclib (HOS-109454) troleandomycin (HOS-090575) ritonavir (HOS-084521) mifepristone (HOS-150754) tucatinib (HOS-145562) posaconazole (HOS-085622) idelalisib (HOS-116811)